This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes; obesity	Acetyl-coenzyme A carboxylase- β (ACACB; ACC2)	<p>Mouse studies suggest inhibiting ACC2 could help treat or prevent metabolic diseases. In mice fed a high-fat and high-cholesterol diet, <i>Acc2</i> knockout decreased serum glucose and triglyceride levels, fat pad size and total body weight compared with wild-type <i>Acc2</i> expression. <i>Acc2</i> knockout mice fed a normal or high-fat diet had greater lipogenic enzyme expression than wild-type controls fed the same diet, suggesting that inhibiting <i>Acc2</i> could protect against metabolic syndrome despite increasing lipogenesis. Next steps include developing an ACC2 inhibitor that can completely block enzyme activity.</p> <p>Accera Inc.'s AC-8632, a nonselective ACC2 inhibitor, is in preclinical testing to treat Parkinson's disease (PD).</p> <p>SciBX 5(11); doi:10.1038/scibx.2012.280 Published online March 15, 2012</p>	Patent status not applicable; unavailable for licensing	<p>Abu-Elheiga, L. <i>et al. J. Biol. Chem.</i>; published online Feb. 23, 2012; doi:10.1074/jbc.M111.309559 Contact: Salih J. Wakil, Baylor College of Medicine, Houston, Texas e-mail: swakil@bcm.edu</p>